David J. Matlin - 31 Jul 2025 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Reporting relationship: Director
Issuer ticker: TLSI
Reported as of: 31 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2026, 16:09:16 UTC
Prior SEC filing: 27 Jun 2025
Next SEC filing: 15 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Mary Szela, Attorney-in-Fact

Key filing fact

David J. Matlin filed Form 4 for TriSalus Life Sciences, Inc. (TLSI) on 01 Apr 2026.

Key facts

This page summarizes David J. Matlin's Form 4 filing for TriSalus Life Sciences, Inc. (TLSI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Apr 2026, 16:09.

Change

Previous filing in this sequence was filed on 27 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001251956 Primary reporting owner

MATLIN DAVID J

Relationship: Director
Address: 6272 W. 91ST AVENUE, WESTMINSTER
Signature: /s/ Mary Szela, Attorney-in-Fact
Signature date: 01 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TLSI transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +330,000
Change %: +35%
Price: $0.000000^*
Shares after: 1,271,944
Date: 31 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TLSI transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -100,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 31 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 330,000
Exercise price: $4.00
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II.

Footnote F2

Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share.

Footnote F3

On July 31, 2025, all 100,000 shares of Preferred Stock held by the Reporting Person were converted into 330,000 shares of Common Stock pursuant to the Offer.